NCT04449276View on ClinicalTrials.gov

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

December 21, 2021

Study Completion Date

December 21, 2021

Conditions
Severe Acute Respiratory SyndromeCoronavirusSARS-CoV-2COVID-19
Interventions
BIOLOGICAL

CVnCoV Vaccine

Participants will receive an intramuscular injection by needle in the deltoid area.

DRUG

Placebo

Participants will receive an intramuscular injection by needle in the deltoid area.

Trial Locations (4)

9000

Universitair Ziekenhuis Ghent, Ghent

30625

Medical University Hannover (MHH), Hanover

72074

University Hospital Tübingen Institut für Tropenmedizin, Tübingen

80802

Ludwig-Maximilians-Universität München, München

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

CureVac

INDUSTRY